This paper presents a case study of a 53-year-old female with a dynamic and obstructive form of HCM. The study includes a case presentation, clinical findings, investigations, and management.

Researchers at ACC's annual meeting reported first-in-human data from a clinical trial of TN-201 that suggested symptom improvement.

It is possible to live with HCM for decades before it is identified by a doctor. There are two main types of HCM: obstructive and nonobstructive. Though both types can impact how well the heart ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this biotech and its assets.

Camzyos (mavacamten) is a prescription drug that works to treat obstructive hypertrophic cardiomyopathy (HCM) by relaxing your heart muscle, allowing it to pump blood more easily. Doctors ...